Abbott Laboratories (ABT) Stock Analysis

Verdict: WATCH (do not buy)

Exact Sciences integration and the 2027 Nutrition spin-off unlock high-margin medtech upside, but $32.6B debt and EPS dilution constrain near-term returns.

Investment score: 58/100

Analysis as of

Is Abbott Laboratories stock worth reviewing? The TradeMates thesis

The model sees Abbott as a high-quality medtech giant undergoing a significant structural transition. The acquisition of Exact Sciences ($21B equity value) and the announced October 2026 tax-free spin-off of the Nutrition division by late 2027 position Abbott as a higher-margin medtech pure play. However, near-term upside is capped by debt leverage ($32.60B total debt) and M&A dilution.

7-factor investment score

Abbott Laboratories opportunities and risks

What speaks for ABT

What speaks against ABT

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
ABT38.0x3.7x21.1x57.1%9.7%4.9%
ISRG52.7x13.5x35.5x67.2%25.5%2.3%
SYK31.4x4.5x19.3x65.2%14.4%4.0%
BSX18.5x3.2x13.5x71.2%17.5%5.5%
BDX59.7x2.6x15.7x46.1%4.5%4.8%
EW51.2x7.9x31.1x78.0%15.4%2.8%
Peer median51.2x4.5x19.3x67.2%15.4%4.0%

Frequently asked questions about Abbott Laboratories (ABT)

Is ABT stock a good investment?

The TradeMates model rates Abbott Laboratories as WATCH (do not buy) with an investment score of 58/100. The model sees Abbott as a high-quality medtech giant undergoing a significant structural transition. The acquisition of Exact Sciences ($21B equity value) and the announced October 2026 tax-free spin-off of the Nutrition division by late 2027 position Abbott as a higher-margin medtech pure play. However, near-term upside is capped by debt leverage ($32.60B total debt) and M&A dilution. This is algorithmic model output, not personal investment advice.

Is ABT stock a buy?

The TradeMates model verdict for ABT is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.